Treatment News : Another HIV Vaccine Trial Ends in Defeat

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » October 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


October 8, 2013

Another HIV Vaccine Trial Ends in Defeat

The search for an HIV vaccine took yet another hit as a major trial was halted early because the vaccine under investigation showed no protective effect, MedPage Today reports. Publishing their findings in The New England Journal of Medicine and also presenting them at the AIDS Vaccine 2013 conference in Barcelona, investigators had enrolled in their trial a total of 2,504 men who have sex with men (MSM) and transgender women who have sex with men.

After a series of injections, the participants were followed for 24 months. At the point when the safety committee put a stop to the trial, 1,914 participants qualified for analysis. Twenty-seven members of the vaccine group and 21 in the placebo group acquired HIV. The difference was not statistically significant, meaning it could have occurred by chance.

The vaccine used a collection of segments of DNA derived from HIV in order to prime the immune system.  Next an adenovirus vector expressing HIV proteins was given as an immune booster.

Despite the fact that the vaccine prompted both cellular and humoral immune response, it failed to lower what’s known as the viral set-point, which is the level at which the viral load eventually reaches a homeostasis—or equilibrium—without antiretroviral intervention. The average viral load for both groups was around 30,000.

Appeasing a major concern of the researchers, the vaccine did prove safe.

To read the MedPage Today story, click here.
To read the study, click here.

Search: HIV vaccine, failure, AIDS Vaccine 2013, MedPage Today, The New England Journal of Medicine.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:

  comments 1 - 1 (of 1 total)    

S. McLaughlin, Washington, DC, 2013-10-09 18:20:32
attenuated whole virus vaccine coupled with HAART should be tried. The adenovirus vector vaccines were a dud years ago. Why repeat the same mistake? Waste of money.

comments 1 - 1 (of 1 total)    

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.